List of Excipients in Branded Drug OXYCONTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT Rx USA LLC	OXYCONTIN	oxycodone hydrochloride	16590-616	BUTYLATED HYDROXYTOLUENE
STAT Rx USA LLC	OXYCONTIN	oxycodone hydrochloride	16590-616	FERRIC OXIDE RED
STAT Rx USA LLC	OXYCONTIN	oxycodone hydrochloride	16590-616	HYPROMELLOSES
STAT Rx USA LLC	OXYCONTIN	oxycodone hydrochloride	16590-616	MAGNESIUM STEARATE

OxyContin Excipient Strategy and Commercial Opportunities

Last updated: September 14, 2026

OxyContin is an extended-release oxycodone hydrochloride tablet whose commercial differentiation depends on its abuse-deterrent formulation, manufacturing controls, and regulatory labeling rather than on a novel active ingredient. The core excipient opportunity is in high-molecular-weight polyethylene oxide, matrix engineering, coating systems, and controlled-release manufacturing processes. Generic competition has reduced the value of the original oxycodone formulation, while abuse-deterrent opioid technology remains commercially relevant for branded opioids, generic development, and contract manufacturing.

What excipients are used in OxyContin?

OxyContin contains oxycodone hydrochloride in a controlled-release tablet matrix. The inactive ingredients include polymers, fillers, lubricants, glidants, coating materials, and colorants. The formulation varies by tablet strength.

Formulation element	Commercial function
High-molecular-weight polyethylene oxide	Creates a robust hydrophilic matrix and increases resistance to crushing and solvent extraction
Lactose monohydrate	Diluent and tablet-mass component
Povidone	Binder and processing aid
Magnesium stearate	Lubricant
Talc	Processing and anti-adherence aid
Hypromellose	Film coating and barrier polymer
Polyethylene glycol	Coating plasticizer
Titanium dioxide and iron oxides	Opacifying and colorant agents

The most commercially important excipient is polyethylene oxide, particularly the high-molecular-weight grade used to form the abuse-deterrent matrix. The matrix hydrates and becomes viscous when exposed to liquid. That behavior makes the tablet more difficult to pulverize, dissolve, inject, or rapidly release than the original formulation.

The formulation is not abuse-proof. FDA labeling states that OxyContin is designed to deter, rather than prevent, abuse by routes including crushing, chewing, snorting, or injection.[1]

How does OxyContin’s abuse-deterrent excipient system work?

OxyContin’s excipient system uses matrix hardness and viscosity as the primary abuse-deterrent mechanisms.

The tablet is designed to resist mechanical manipulation. When exposed to water or other liquids, the polyethylene oxide matrix forms a viscous gel. The resulting material is difficult to draw into a syringe and limits rapid extraction of oxycodone. The system also maintains extended release when the dosage form is taken as directed.

The formulation strategy has four technical requirements:

1. Sufficient mechanical strength to resist crushing.
2. Controlled hydration and gel formation.
3. Consistent oxycodone diffusion over the labeled dosing interval.
4. Manufacturability across tablet strengths and production lots.

Increasing polymer molecular weight or concentration can improve abuse-deterrent performance but may create processing and dissolution problems. Excessive polymer content can increase compression force, slow dissolution beyond the target profile, produce sticking during tableting, or create strength-to-strength variability.

Which excipient properties matter most?

The critical attributes for polyethylene oxide include:

• Molecular weight distribution
• Viscosity grade
• Moisture content
• Particle-size distribution
• Bulk density
• Flowability
• Compression behavior
• Hydration rate
• Compatibility with oxycodone hydrochloride
• Thermal and shear stability

Supplier qualification is important because small changes in polymer grade can affect tablet hardness, dissolution, gel strength, and abuse-deterrence testing.

What formulations are protected by OxyContin patents?

OxyContin’s protection has involved several layers:

• Controlled-release oxycodone formulations
• Polymer-based matrix tablets
• Abuse-deterrent dosage forms
• Tablet manufacturing processes
• Method-of-use claims
• Strength-specific and formulation-specific regulatory protections

The original controlled-release formulation patents have largely reached the end of their commercial life. The reformulated abuse-deterrent product created a later layer of intellectual-property protection, but patent protection does not prevent all generic oxycodone extended-release products from entering the market.

FDA’s Orange Book identifies patents and regulatory exclusivities associated with approved drug products. The relevant record is the OxyContin NDA 20-553 listing and associated patent certifications filed by abbreviated new drug applicants.[2]

How strong is the OxyContin patent estate?

The estate is stronger around formulation know-how and manufacturing execution than around the basic active ingredient.

Protection category	Current commercial strength
Oxycodone active ingredient	None; oxycodone is a long-established generic opioid
Original controlled-release formulation	Limited because core patent terms have expired or approached expiration
Abuse-deterrent matrix	More relevant, but vulnerable to design-around formulations
Manufacturing process	Potentially meaningful if process claims are narrow and difficult to reproduce
Method of use	Limited for ordinary chronic pain treatment because generic applicants can use carve-outs
Trade secrets and know-how	Potentially strong where process parameters are not disclosed in patents

The most defensible assets are likely to be the combination of polymer selection, particle engineering, compression conditions, coating parameters, and dissolution-control methods. Patent claims directed only to a general polymer matrix are easier to challenge or design around than claims tied to a narrow performance profile.

When does OxyContin lose exclusivity?

OxyContin no longer has the exclusivity profile of a newly launched branded drug. The product’s key commercial milestones are:

Date	Event
1995	FDA approved the original OxyContin extended-release oxycodone product
1996	Commercial launch of OxyContin
2010	Purdue introduced a reformulated product using abuse-deterrent technology
2013	FDA approved abuse-deterrent labeling for reformulated OxyContin
2013 onward	Generic oxycodone extended-release products entered the U.S. market
Current period	Brand value depends on formulation differentiation, contracting, and regulatory status rather than basic molecule exclusivity

OxyContin’s market exclusivity and patent protection are separate concepts. FDA regulatory exclusivity may expire before or after particular patents. Patent expiry also does not guarantee immediate generic substitution if an applicant lacks an approved product, faces controlled-substance quotas, or cannot reproduce the required release profile.

What is the FDA regulatory status of OxyContin?

OxyContin is an FDA-approved Schedule II opioid analgesic indicated for the management of pain severe enough to require a daily, around-the-clock, long-term opioid treatment when alternative treatments are inadequate.[1]

The reformulated product carries abuse-deterrent labeling. FDA’s abuse-deterrent guidance evaluates whether a product is resistant to one or more forms of manipulation. The designation does not establish that the product is safe from abuse or that it prevents addiction, overdose, or diversion.[3]

The regulatory value of the formulation includes:

• A differentiated label
• Additional development requirements for generic applicants seeking comparable abuse-deterrent claims
• Greater difficulty reproducing the tablet’s physical and chemical behavior
• Potential contracting advantages in institutional channels
• A basis for lifecycle-management products using related opioid matrices

A generic oxycodone extended-release product can compete without carrying the same abuse-deterrent claim, depending on the reference product and FDA approval pathway.

How many patents cover OxyContin?

The exact count changes as FDA Orange Book listings expire, are delisted, or become legally irrelevant. The relevant patent categories include controlled-release composition patents, abuse-deterrent formulation patents, manufacturing patents, and method-of-use patents.

Patent review should distinguish among:

• Patents listed in the Orange Book
• Unlisted formulation patents
• Expired patents
• Patents subject to pediatric extensions
• Patents challenged under Paragraph IV
• Patents that cover only the branded formulation and not all oxycodone extended-release products

A patent family can be commercially important even when it does not block every generic. For example, a patent covering a specific high-molecular-weight polymer matrix may not prevent a competitor from using a different polymer, compression profile, coating, or release mechanism.

Which companies are challenging OxyContin?

Generic competition has come from manufacturers developing oxycodone hydrochloride extended-release tablets through the ANDA pathway. The competitive field has included major generic manufacturers and specialty pharmaceutical companies with controlled-substance infrastructure.

Paragraph IV challenges are commercially significant because an ANDA applicant may assert that listed patents are invalid, unenforceable, or not infringed. The resulting litigation can delay approval, restrict labeling, or produce a settlement with a negotiated launch date.

For OxyContin, the main competitive variables are:

• Whether the applicant seeks abuse-deterrent labeling
• Whether the product references the reformulated product
• Whether the applicant uses a non-infringing polymer system
• Controlled-substance manufacturing capacity
• DEA quota availability
• Ability to scale high-potency opioid production
• State and payer restrictions

What patent litigation and settlements affect OxyContin?

OxyContin has been involved in extensive litigation concerning patents, generic entry, marketing conduct, and opioid-related liability. Patent litigation has focused on whether generic applicants can enter before the expiry of listed patents and whether formulation claims withstand validity and infringement challenges.

Separate opioid litigation has involved Purdue Pharma, state governments, municipalities, private plaintiffs, and bankruptcy proceedings. Those matters affect the commercial environment, corporate ownership, licensing capacity, and willingness of counterparties to enter new OxyContin-related transactions. They do not automatically determine the validity of individual formulation patents.

A settlement can provide an authorized-generic or negotiated entry path. Such arrangements may reduce patent litigation costs but compress the branded product’s remaining price premium.

What commercial opportunities exist for OxyContin excipients?

The largest opportunity is not a new OxyContin launch. It is the supply and licensing of technologies that address controlled-release performance and abuse deterrence.

High-molecular-weight polyethylene oxide

Excipient suppliers can compete through:

• Pharmaceutical-grade polymer consistency
• Multiple viscosity grades
• Low-moisture material
• Improved flow and compaction
• Supply-chain redundancy
• Regulatory documentation
• Small-scale development quantities
• Technical support for dissolution and abuse-deterrence studies

A qualified second source can have high value because opioid manufacturers face production interruptions, quota constraints, and strict batch-release controls.

Alternative matrix polymers

Potential substitutes include hypromellose, hydroxypropyl cellulose, carbomers, polymethacrylates, and polymer blends. Each has tradeoffs in hydration, gel strength, drug release, compression, and extraction resistance.

The commercial opportunity is strongest where an alternative polymer can:

• Match the reference product’s release profile
• Avoid a blocking patent claim
• Reduce tablet weight
• Improve manufacturability
• Reduce dependence on a single supplier
• Preserve abuse-deterrent performance

Coatings and multilayer tablets

Coating suppliers can develop systems that improve moisture protection, mechanical strength, swallowability, and product identification. Multilayer or compression-coated tablets may provide additional separation between immediate-release and extended-release components, although they increase manufacturing complexity.

Analytical and testing services

Specialized laboratories can support:

• Crush-resistance testing
• Particle-size analysis after manipulation
• Solvent extraction studies
• Syringeability testing
• In vitro release testing
• Comparative abuse-deterrence assessment
• Stability testing under high humidity and temperature
• Extractables and leachables evaluation

These services are useful to generic developers, reformulation programs, and excipient suppliers seeking qualification in opioid products.

How does OxyContin compare with competing opioid formulations?

Product type	Primary differentiation	Excipient opportunity	Generic risk
Original oxycodone ER	Controlled release	Conventional hydrophilic matrices	High
Reformulated OxyContin	Abuse-deterrent matrix	High-molecular-weight polymers and coatings	Moderate to high
Oxycodone immediate release	Rapid systemic delivery	Standard tablet and capsule excipients	Very high
Abuse-deterrent hydrocodone ER	Manipulation resistance	Polymer matrices and coatings	Moderate
Transdermal opioid systems	Delivery through skin	Adhesives, permeation enhancers, backing layers	Product-specific
Long-acting injectable opioids	Depot release	Microspheres, suspensions, biodegradable polymers	Lower near-term substitution risk

OxyContin’s excipient platform is most comparable with other abuse-deterrent oral opioid technologies. It is less comparable with transdermal or injectable products, where the commercial value lies in delivery-device and depot technology rather than tablet matrix design.

What generic entry risks exist?

Generic entry risk remains high for non-abuse-deterrent oxycodone extended-release products. A generic applicant does not necessarily need to replicate every commercial attribute of the branded formulation unless those attributes are required by the reference product, patent claims, or the proposed label.

The main risks to branded revenue are:

• Price erosion from multiple ANDA approvals
• Payer preference for lower-cost alternatives
• Therapeutic substitution among opioid products
• Reduced physician prescribing
• Institutional purchasing restrictions
• State-level opioid controls
• Product shortages that shift volume between suppliers

The main barriers to generic entry are controlled-substance regulation, manufacturing quotas, bioequivalence requirements, dissolution matching, formulation patents, and the cost of abuse-deterrence development.

What is the revenue exposure for OxyContin and its excipient suppliers?

OxyContin’s historical revenue was concentrated in the U.S. branded opioid market. The commercial base has contracted because of generic competition, opioid-prescribing restrictions, litigation, and reduced use of long-term opioid therapy.

Excipient suppliers have a different exposure profile. A polymer supplier may sell into multiple controlled-release products and is less dependent on OxyContin itself. The strongest business models include:

• Multi-customer pharmaceutical-grade polymer platforms
• Dual sourcing and supply assurance
• Formulation-development partnerships
• Technical licensing
• Contract development and manufacturing
• Analytical testing for abuse-deterrent products
• Expansion into non-opioid controlled-release medicines

Key Takeaways

• OxyContin’s principal excipient technology is a high-molecular-weight polyethylene oxide matrix.
• The formulation’s commercial differentiation comes from abuse deterrence, not from oxycodone itself.
• The highest-value technical parameters are polymer grade, molecular weight, hydration behavior, compression, and dissolution control.
• Generic competition has weakened the branded product’s pricing power.
• Formulation patents and manufacturing know-how remain more important than active-ingredient protection.
• Commercial opportunities are strongest in polymer supply, alternative abuse-deterrent matrices, coatings, analytical testing, and contract development.
• Biosimilar risk is not applicable because OxyContin is a small-molecule opioid, not a biologic.
• FDA Orange Book listings, ANDA certifications, patent status, and controlled-substance manufacturing capacity determine the practical risk of generic entry.

FAQs

Does OxyContin contain polyethylene oxide?

Yes. Polyethylene oxide is a central component of the abuse-deterrent controlled-release matrix described in OxyContin’s FDA labeling.

Can a generic use different excipients from OxyContin?

Yes. A generic applicant can use a different excipient system if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling.

Is OxyContin abuse-deterrent technology patented?

Abuse-deterrent formulation technology has been protected through patent families covering polymer matrices, dosage forms, and manufacturing approaches. The commercial effect of each patent depends on its claims, term, Orange Book listing, and litigation history.

Are OxyContin excipients suitable for other controlled-release drugs?

Yes. Polyethylene oxide, hypromellose, coating polymers, and related excipients are used across controlled-release products. Performance must be requalified for each active ingredient, dose, tablet geometry, and release target.

Is there biosimilar competition to OxyContin?

No. OxyContin contains oxycodone hydrochloride, a small-molecule active ingredient. Competition proceeds through generic drug pathways, primarily ANDAs, rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2023). OxyContin (oxycodone hydrochloride) extended-release tablets prescribing information. Purdue Pharma L.P.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling.